Interactions with herbs
Ginkgo Biloba
Licorice
  Interactions with supplements
Calcium
Vitamin D
Look Up > Drugs > Cyclothiazide
Cyclothiazide
Pronunciation
U.S. Brand Names
Generic Available
Pharmacological Index
Pregnancy Risk Factor
Contraindications
Warnings/Precautions
Adverse Reactions
Drug Interactions
Usual Dosage
Monitoring Parameters
Test Interactions
Cardiovascular Considerations
Dosage Forms
References

Pronunciation
(sye kloe THYE a zide)

U.S. Brand Names
Anhydron®

Generic Available

Yes


Pharmacological Index

Diuretic, Thiazide


Pregnancy Risk Factor

C


Contraindications

Hypersensitivity to cyclothiazide or any component; cross-sensitivity with other thiazides or sulfonamides; anuria; renal decompensation


Warnings/Precautions

Use with caution in severe renal disease. Electrolyte disturbances (hypokalemia, hypochloremic alkalosis, hyponatremia) can occur. Use with caution in severe hepatic dysfunction; hepatic encephalopathy can be caused by electrolyte disturbances. Gout can be precipitate in certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure. Cautious use in diabetics; may see a change in glucose control. I.V. use is generally not recommended (but is available). Hypersensitivity reactions can occur. Can cause SLE exacerbation or activation. Use with caution in patients with moderate or high cholesterol concentrations. Photosensitization may occur. Correct hypokalemia before initiating therapy.


Adverse Reactions

1% to 10%: Hypokalemia

<1% (Limited to important or life-threatening symptoms): Hypotension, fluid and electrolyte imbalances (hypocalcemia, hypomagnesemia, hyponatremia), hyperglycemia, rarely blood dyscrasias, prerenal azotemia, photosensitivity


Drug Interactions

Angiotensin-converting enzyme inhibitors: Increased hypotension if aggressively diuresed with a thiazide diuretic.

Beta-blockers increase hyperglycemic effects in Type 2 diabetes mellitus.

Cyclosporine and thiazides can increase the risk of gout or renal toxicity; avoid concurrent use.

Digoxin toxicity can be exacerbated if a thiazide induces hypokalemia or hypomagnesemia.

Lithium toxicity can occur by reducing renal excretion of lithium; monitor lithium concentration and adjust as needed.

Neuromuscular blocking agents can prolong blockade; monitor serum potassium and neuromuscular status.

NSAIDs can decrease the efficacy of thiazides reducing the diuretic and antihypertensive effects.


Usual Dosage

Adults: Oral: 2 mg/day; up to 2 mg 2-3 times/day


Monitoring Parameters

Serum electrolytes, renal function, blood pressure, I & O, weight


Test Interactions

ammonia (B), amylase (S), calcium (S), chloride (S), cholesterol (S), glucose, uric acid (S); chloride (S), magnesium, potassium (S), sodium (S)


Cardiovascular Considerations

Thiazide diuretics are effective first-line therapeutic agents in the management of hypertension and have proven to be of benefit in terms of cardiovascular outcome. They may act synergistically to lower blood pressure when combined with an ACE inhibitor or beta-blocker. The initial concern about thiazide diuretic-induced hypokalemia, glucose intolerance, and lipid profiles does not appear to be of substantial clinical consequence in the treatment of hypertension. The benefits of this class of agents in the treatment of hypertension is established and compares well with other first-line therapeutic agents.


Dosage Forms

Tablet: 2 mg


References

"Consensus Recommendations for the Management of Chronic Heart Failure. On Behalf of the Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure," Am J Cardiol, 1999, 83(2A):1A-38A.

Gibbons RJ, Chatterjee K, Daley J, et al, "ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines," J Am Coll Cardiol, 1999, 33(7):2092-197.

Ryan TJ, Anderson JL, Antman EM, et al, "ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)," J Am Coll Cardiol, 1996, 28(5):1328-428.

"The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure," Arch Intern Med, 1997, 157(21):2413-46.


Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved